Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro

Overview of attention for article published in Breast Cancer Research and Treatment, February 2007

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

So far, Dimensions has found 354 publications that cite this research output.

Article in Biomedicines (May 2024)

Article in Epigenetics (February 2024)

Article in Bioorganic Chemistry (January 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.